Efficacy of Clopidogrel Plus Aspirin in Selected Clinical Trials
| Trial | Patient Population | Endpoint | Event Rate Combination (%) | Event Rate Monotherapy (%) | P |
|---|---|---|---|---|---|
| CHARISMA (3) | CAD | CV death, MI, or CVA at 28 months | 6.8 | 7.3 | .22 |
| MATCH (5) | CVA | CVA, MI, CV death, or CV hospitalization at 18 months | 15.7 | 16.7* | .244 |
| CLARITY (6) | STEMI | Occlusion, death, or recurrent MI at 8 days | 15 | 21.7 | <.001 |
| CURE (9) | NSTEMI | CV death, MI, or CVA at 12 months | 9.3 | 11.4 | <.001 |
| PCI-CURE (12) | NSTEMI with PCI | CV death or MI at 8 months | 8.8 | 12.6 | .002 |
| CREDO (11) | PCI | Death, MI, or CVA at 12 months | 8.5 | 11.5 | .02 |
* Clopidogrel monotherapy.
CHARISMA, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance; MATCH, Management of Atherothrombosis with Clopidogrel in High-Risk Patients; CLARITY, Clopidogrel as Adjunctive Reperfusion Therapy; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent Events; PCI-CURE, Percutaneous Coronary Intervention in the Clopidogrel in Unstable Angina to Prevent Recurrent Events; CREDO, Clopidogrel for the Reduction of Events During Observation; CAD, coronary artery disease; CVA, cardiovascular accident; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; CV, cardiovascular; MI, myocardial infarction.